Navigation Links
For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients
Date:12/8/2010

apies -- Roche/Genentech/Chugai's Avastin, Eisai/Morphotek's farletuzumab, AstraZeneca's olaparib and Sanofi-Aventis' iniparib. Avastin will be the first targeted therapy to enter the market, following its expected approval in the U.S. and Europe in 2012 and in Japan in 2014.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Pharmacor Patient Flow ModelsBy utilizing our proprietary Pharmacor epidemiological data, Decision Resources now provides Pharmacor Patient Flow Models covering ovarian cancer, renal cell carcinoma, pancreatic cancer and colorectal cancer. Using Pharmacor Patient Flow Models, users can build their own oncology patient flow model and/or validate the logic behind their own internal models. This interactive tool allows users to track changing disease and population dynamics over a 15-year annualized forecast, improve their modeling accuracy with clearly depicted methods and transparent assumptions and identify untapped market potential within lines of therapy. Pharmacor Patient Flow Models is available as an add-on product to the Pharmacor advisory service.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015  Delays in the launch ... slow down the decision-making process, resulting in missed ... critical for biopharmaceutical companies to develop a tactical ... for quicker and more meaningful insights. ... LLC, nearly three-quarters of benchmarked study participants use ...
(Date:8/28/2015)... According to a new market ... Prostate) Type (Protein & Genetic Biomarkers) Profiling Technology (Proteomics, ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... 17,689.0 Million USD by 2020 at a CAGR of ... Browse 191 Tables and 38 F ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/686gwf/investigation ... Report on China,s Bevacizumab Market ,2010-2019" report to ... trade name of Avastin, bevacizumab injection is the first ... was approved by CFDA to treat metastatic colorectal cancer. ... all come from Roche and its subsidiary Genectech. ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 5Investigation Report on China's Bevacizumab Market 2015-2019 2
... Radiologists are using a new minimally,invasive procedure to ... reduces pain from calcific tendonitis of,the rotator cuff ... at the annual meeting of the Radiological Society ... successful and inexpensive therapy for tendon,calcifications," said Luca ...
... releases data on minimally invasive alternative to ... ... Bio-Surfaces, Inc. (ABS),announced today the availability of OrthoGlide Medial Knee ... of enrollment in the,OrthoGlide clinical study was presented on November ...
Cached Medicine Technology:Minimally Invasive Treatment Reduces Shoulder Pain From Tendonitis 2Minimally Invasive Treatment Reduces Shoulder Pain From Tendonitis 3Clinical Data Presented on OrthoGlide(R) Medial Knee Implant 2
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... has selected ezDI’s computer-assisted coding (CAC) software for its Clinical Documentation Improvement (CDI) ... ezNLP, and a patent pending ICD-10 solution - ezCAC is an enterprise-level coding ...
(Date:8/31/2015)... , ... August 31, 2015 , ... Castle Dermatology Institute ... practice. Dr. Pedram Ghasri is a graduate of the University of California, Los Angeles. ... his studies at the University of California, Irvine Medical School. As a nationally recognized ...
(Date:8/31/2015)... ... August 31, 2015 , ... “My mother and husband ... inventor, from Hagerhill, Ky. “I thought there could be a comfortable way to prevent ... The Nasal Cannula Ear Protector offers a more secure way to anchor the cannula ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... A year ... the team is preparing to release a new issue commemorating the successful first year. ... information they need for a potentially difficult time in their lives,” says Melissa Wolfert, ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s big news for ... the digital healthcare industry. , Consumer driven health plans (CDHPs) are a growing ... advisory and strategic role to the company, and another to answer customers’ questions directly. ...
Breaking Medicine News(10 mins):Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 3Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 4Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 2Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 3Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 3
... Mountain View, CA December 5, 2008 ... on developing technologies and products for immune disorders, ... therapeutic treatment for Graft versus Host Disease (GvHD) ... being held December 6 through 9 in San ...
... pseudoephedrine for kids under 2 poses toxicity issues because ... -- Exposure to the decongestant pseudoephedrine, found in many ... among children in the United States. , This is ... the highest risk for toxicity and for whom safe ...
... a USGS study released today,showing that man-made chemicals remained ... the Water Quality Association is encouraging consumers,to educate themselves ... According to a report by the U.S. Geological ... removed by public treatment processes. The,USGS examined water ...
... Launched by Product Stewardship Institute and King Pharmaceuticals ... 5 /PRNewswire-USNewswire/ - - The Product Stewardship ... Dialogue Meeting earlier this week in Washington, DC ... medications to combat increasing rates of prescription drug abuse, ...
... AIDS-causing virus don,t get sick , , FRIDAY, Dec. 5 (HealthDay ... of how a small number of HIV-infected people manage to ... medicine. , The key seems to be an unusual feature ... hope it might lead to better drug therapies or even ...
... another reason to quit smoking, consider that it may diminish ... the University of Rochester Medical Center have found that women ... were significantly more likely to face fertility problems and suffer ... non-smoking women showed those who were exposed to second hand ...
Cached Medicine News:Health News:Decongestant Exposure Needs Closer Look 2Health News:Chemicals Remain in Most Treated Water, Says Report 2Health News:Leading Government and Advocacy Stakeholders Engage in Public Health Dialogue on Improving Disposal of Unused Medications 2Health News:Leading Government and Advocacy Stakeholders Engage in Public Health Dialogue on Improving Disposal of Unused Medications 3Health News:Leading Government and Advocacy Stakeholders Engage in Public Health Dialogue on Improving Disposal of Unused Medications 4Health News:Special Immune Cells May Be Key to HIV Resistance 2Health News:Secondhand smoke raises odds of fertility problems in women 2
... a two chain (alpha- and beta-subunits) glycoprotein ... the placenta and is normally found in ... the trophoblastic epithelium of the placenta, hCG ... the early stages of pregnancy. The primary ...
... for movement is critical ... wheelchairs. Thats why this ... technology to do just ... state-of-the-art technology, these wheelchair ...
When patients are less mobile our ProPlus™ Stand-On Scale with built-in wheels moves easily to them. Extremely durable and safe, the easy grip handrail and non-skid platform provide added suppo...
... 100 provides a new screening, diagnostic, treatment ... medical management of sleep-related breathing disorders. The ... unmet need for an ambulatory, reliable, patient ... to the great number of OSA sufferers, ...
Medicine Products: